GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

Trial Profile

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs GM 6 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms GALS
  • Sponsors Genervon Biopharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Sep 2015 Results published in the Media Release.
    • 28 Apr 2014 Preliminary data reported in a Genervon Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top